Ro starts selling discounted Zepbound vials in a deal with Lilly

Eli Lilly announced a new partnership with telehealth platform Ro on Dec. 11, 2024, making Ro the first company besides Lilly's own site to sell discounted single-dose vials of Zepbound (tirzepatide) ^[1][2]. Under the deal, patients who get a Zepbound prescription through a Ro-affiliated provider can now have vials delivered to their homes through an integration with Lilly's direct-to-consumer site, LillyDirect ^[2].

The vials are dispensed by a third-party digital pharmacy called Gifthealth, which already handled vial orders placed directly through LillyDirect ^[2]. Ro says the arrangement creates a "complete end-to-end" experience, letting patients get a diagnosis, prescription, and delivery from one app instead of visiting a doctor's office and a separate pharmacy ^[2].

Price is central to the deal. The 2.5-milligram vial costs $399 a month and the 5-milligram vial costs $549 a month, before insurance, compared with roughly $1,000 a month for Zepbound's autoinjector pen, also before insurance ^[2]. Lilly began selling these vials through LillyDirect in August 2024, and Ro's CEO, Zachariah Reitano, called them the "most affordable branded cash-pay GLP-1" on the market, while acknowledging that $400 to $500 a month is "still out of reach for many" even if it is more accessible than $1,000 ^[2].

The timing is not a coincidence. Ro had been one of the major telehealth platforms selling compounded copies of GLP-1 drugs during the branded shortages, and Lilly has been aggressive about pushing back on compounded tirzepatide, including sending cease-and-desist letters to telehealth companies offering it ^[1]. At the time of the announcement, the FDA was reconsidering its decision to remove Zepbound from the drug shortage list after a lawsuit from a trade group representing compounding pharmacies — a decision that, if it stands, would largely end compounding pharmacies' ability to make custom tirzepatide ^[2]. Lilly's Patrik Jonsson, president of cardiometabolic health, said the goal of the integration was to "break down barriers and provide patients with safe and effective options they can rely on" ^[2].

Why it matters for patients

For patients without insurance coverage for Zepbound, the vial option through Ro offers a lower cash price than the pen, which could make the branded drug more attainable as compounded versions become harder to access ^[2]. But the vials still cost hundreds of dollars a month, which Ro's own CEO said remains out of reach for some people ^[2]. Patients who had been relying on compounded tirzepatide through Ro or similar platforms may need to weigh switching to a costlier branded product against uncertainty over whether compounded versions will remain legally available ^[1][2]. The deal also reflects a broader pattern: Lilly has been working through multiple telehealth partners to steer patients toward its own product and away from compounding pharmacies, which it has criticized directly ^[1].

What happens next

At the time of the announcement, the FDA had not finalized its decision on whether Zepbound would return to, or stay off, the official drug shortage list, a decision being contested in court by a compounding pharmacy trade group ^[2]. Reitano said Ro would follow whatever FDA guidance results, while also working to preserve patient access to what it considers the most effective and affordable products ^[2]. The sources do not specify a date by which the FDA's shortage determination would be finalized.